Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biocon Limited ( (IN:BIOCON) ) just unveiled an update.
Biocon Biologics, a subsidiary of Biocon Limited, has achieved a significant milestone by supplying over 100 million cartridges of recombinant human insulin to Malaysia’s Ministry of Health, serving more than 345,000 patients since 2016. This accomplishment highlights Biocon’s commitment to improving diabetes care and ensuring affordable insulin access in Malaysia, supported by a successful public-private partnership with the Malaysian government and Duopharma Biotech Berhad. The collaboration has strengthened the local biotech ecosystem, advanced insulin self-sufficiency, and reinforced Biocon’s position as a leading player in the global insulin market.
More about Biocon Limited
Biocon Limited is a global biosimilars company primarily involved in the biotechnology industry. It focuses on developing and manufacturing affordable biologics and biosimilars, with a significant emphasis on diabetes care through its insulin products. The company operates a state-of-the-art manufacturing facility in Johor, Malaysia, and collaborates with local partners to enhance healthcare solutions.
Average Trading Volume: 146,880
Current Market Cap: 472.5B INR
For a thorough assessment of BIOCON stock, go to TipRanks’ Stock Analysis page.